Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391807 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of an Oral Contraceptive
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,683
- Enrollment target
NCT00391807 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 1,683 participants.
The verdict
NCT00391807, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,683 participants
- Enrollment target
Study Summary
This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.
Interventions
- DRUG Norethindrone acetate/ethinyl estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,683 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00391807
The ClinicalTrials.gov registry entry for NCT00391807 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,683 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Norethindrone acetate/ethinyl estradiol is the first listed.
NCT00391807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00391807 about?
NCT00391807 is a clinical study titled "Study of Safety and Efficacy of an Oral Contraceptive". This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.
What is the current status of trial NCT00391807?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,683 participants. The study started on 2006-11. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00391807?
The interventions under investigation include: Norethindrone acetate/ethinyl estradiol (DRUG).
Who is sponsoring clinical trial NCT00391807?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.